Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1995-12-04
1999-01-05
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241331, 4241391, 4241431, 435 724, A61K 39395, G01N 3353
Patent
active
058558870
ABSTRACT:
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley
patent: 5556763 (1996-09-01), Ochoa et al.
Walnus, TL. Immunity 1:405-413, Aug. 1994.
Kearney ER J.Immunol 155:1032-1036, Aug. 1995.
Wu et al., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997).
Linsley, P.S., "Distinct Roles for CD28 and Cytotoxic Lymphocyte-Associated Molecule-4 Receptors During T Cell Activation," J. Exp. Med., 182:289-292 (1995).
Damle et al., "Costimulation of T Lymphocytes with Intergrin Ligands Intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, A Second Receptor for B7," Journal of Immunology 152:2686-2697 (1994).
Lin et al., "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4lg Plus Donor-Specific Transfusion," J. Exp. Med. 178:1801-1806 (1993).
Turka et al., "T-Cell Activation by the CD28 Ligand B7 is Required for Cardiac Allograft Rejection in vivo," Proc. Natl. Acad. Sci. USA 89:11102-11105 (1992).
Linsley, P.S. and J.A. Ledbetter, "The Role of the CD28 Receptor During T Cell Responses to Antigen," Ann. Rev. Immunol. 11:191-212 (1993).
Chen et al. (1992) Cell 71:1093-1102.
Walunas et al. (1994) Immunity 1:405-413.
Lenschow et al. (1992) Science 257:789-792.
Linsley et al. (1992) Science 257:792-795.
Lenschow et al. (1993) P.N.A.S. 90:11054-11058.
Freeman et al. (1993) Science 262:907-909.
Linsley et al. (1991) J. Exp. Med. 174:561-569.
Brunet et al. (1987) Nature 328:267-270.
Harding et al. (1994) Nature 356: 607-609.
Schwartz (1992) Cell 71:1065.
Townsend and Allison (1993) Science 259:368.
Linsley et al. (1992) J. Exp. Med. 176:1595-1604.
Gribben et al. (1995) P.N.A.S. 92:811-815.
Jenkins (1994) Immunity 1:443-446.
Bluestone (1995) Immunity 2:555-559.
June et al. (1994) Immunology Today 15:321-331.
Allison James Patrick
Krummel Matthew F.
Leach Dana R.
Scheiner Toni R.
The Regents of the University of California
LandOfFree
Blockade of lymphocyte down-regulation associated with CTLA-4 si does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blockade of lymphocyte down-regulation associated with CTLA-4 si, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of lymphocyte down-regulation associated with CTLA-4 si will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-859734